Skip to content
★ Sign in to follow
WR

Wendye Robbins

Board Director
Director
RAPT Therapeutics, Inc.
Total declarations
51
Company
1
▲ Purchases (49 ops.)
€469k
▼ Sales (0 ops.)
—

Latest filing published 15 Mar 2023 for RAPT Therapeutics, Inc., €26k.

Filing timeline

BuySale
Wendye Robbins

Insider track record

Disclosed buys
49
Disclosed sells
0
Signal history

Closed purchases

Market purchases
49

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Wendye Robbins: trading record in brief

This profile gathers the share dealings of Wendye Robbins in RAPT Therapeutics, Inc., where the filings describe the role as board member. The record holds 51 filings, for trades running from 4 November 2019 to 14 March 2023.

Purchases make up the whole of the open-market record (49 purchases, €469k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2023, the count stands at 1 purchase and no sales.

The median purchase comes to €7,398. On 9 out of 42 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 15 March 2023, reports an open-market purchase of €26k in RAPT Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Wendye Robbins

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations49 total
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    28,125 USD15SEC
    1,500 shares@ US$18.7523.0% of flowCommon StockSEC:0001209191-23-019023:0
    Canonical exit: 12 Jun 2023 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    29,500 USD0SEC
    2,500 shares@ US$11.80Common StockSEC:0001593968-22-000958:1
    Canonical exit: 8 Aug 2022 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    5,650 USD0SEC
    500 shares@ US$11.30Common StockSEC:0001593968-22-000958:2
    Canonical exit: 8 Aug 2022 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    10,510 USD0SEC
    1,000 shares@ US$10.51Common StockSEC:0001593968-22-000958:3
    Canonical exit: 8 Aug 2022 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    6,294 USD0SEC
    600 shares@ US$10.49Common StockSEC:0001593968-22-000958:4
    Canonical exit: 8 Aug 2022 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    4,248 USD0SEC
    400 shares@ US$10.62Common StockSEC:0001593968-22-000958:5
    Canonical exit: 8 Aug 2022 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    21,080 USD34SEC
    2,000 shares@ US$10.5417.6% of flowCommon StockSEC:0001593968-22-000958:0
    Canonical exit: 8 Aug 2022 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    15,350 USD18SEC
    500 shares@ US$30.7011.6% of flowCommon StockSEC:0001593968-21-002279:0
    Canonical exit: 16 Jan 2022 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    11,876 USD18SEC
    400 shares@ US$29.699.0% of flowCommon StockSEC:0001593968-21-002276:0
    Canonical exit: 11 Jan 2022 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    15,750 USD17SEC
    500 shares@ US$31.503.4% of flowCommon StockSEC:0001593968-21-002027:1
    Canonical exit: 21 Nov 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    8,013 USD17SEC
    250 shares@ US$32.051.7% of flowCommon StockSEC:0001593968-21-002027:2
    Canonical exit: 21 Nov 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    6,975 USD17SEC
    225 shares@ US$31.001.5% of flowCommon StockSEC:0001593968-21-002027:3
    Canonical exit: 21 Nov 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    15,500 USD17SEC
    500 shares@ US$31.003.4% of flowCommon StockSEC:0001593968-21-002027:4
    Canonical exit: 22 Nov 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    770 USD17SEC
    25 shares@ US$30.810.2% of flowCommon StockSEC:0001593968-21-002027:5
    Canonical exit: 22 Nov 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    15,557 USD18SEC
    500 shares@ US$31.114411.6% of flowCommon StockSEC:0001593968-21-002027:0
    Canonical exit: 21 Nov 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    14,735 USD17SEC
    500 shares@ US$29.473.2% of flowCommon StockSEC:0001593968-21-002007:1
    Canonical exit: 18 Nov 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    2,982 USD15SEC
    100 shares@ US$29.8152.2% of flowCommon StockSEC:0001593968-21-002007:0
    Canonical exit: 18 Nov 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    12,060 USD17SEC
    400 shares@ US$30.152.6% of flowCommon StockSEC:0001593968-21-001818:1
    Canonical exit: 5 Oct 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    18,120 USD14SEC
    600 shares@ US$30.2013.5% of flowCommon StockSEC:0001593968-21-001818:0
    Canonical exit: 5 Oct 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    3,156 USD17SEC
    100 shares@ US$31.560.7% of flowCommon StockSEC:0001593968-21-001661:1
    Canonical exit: 14 Sept 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    3,153 USD17SEC
    100 shares@ US$31.530.7% of flowCommon StockSEC:0001593968-21-001661:2
    Canonical exit: 14 Sept 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    158 USD17SEC
    5 shares@ US$31.610.0% of flowCommon StockSEC:0001593968-21-001661:3
    Canonical exit: 14 Sept 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    15,770 USD12SEC
    500 shares@ US$31.5411.5% of flowCommon StockSEC:0001593968-21-001661:0
    Canonical exit: 14 Sept 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    7,800 USD17SEC
    400 shares@ US$19.501.7% of flowCommon StockSEC:0001593968-21-001115:0
    Canonical exit: 12 Jul 2021 (T+90)
  • ▲
    DirectorExecutivesRAPT Therapeutics, Inc.
    5,820 USD17SEC
    300 shares@ US$19.401.2% of flowCommon StockSEC:0001593968-21-001115:1
    Canonical exit: 12 Jul 2021 (T+90)

25 of 49 declarations